Top Markets
Coin of the day
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Rang in aandelen #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Aandeelprijs
$9.50
Laatst gesynchroniseerd: 2025-01-08
Marktkapitalisatie
$819.52M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Poseida Therapeutics, Inc. (PSTX)

Categorie

Winst voor Poseida Therapeutics, Inc. (PSTX)
Winst in Sep 2024 TTM: $-60.72M
Volgens de meest recente financiële verslagen van Poseida Therapeutics, Inc. bedraagt de huidige winst van het bedrijf $-60.72M. In 2022 behaalde het bedrijf een winst van $-63.46M, een daling ten opzichte van de winst van 2021, die $-124.97K bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Poseida Therapeutics, Inc. van 2016 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-60.72M -50.77%
2023 $-123.32M 94.34%
2022 $-63.46M 50,676.96%
2021 $-124.97K -3.70%
2020 $-129.78K -99.85%
2019 $-86.53M 93.98%
2018 $-44.61M 120.94%
2017 $-20.19M 278.07%
2016 $-5.34M 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$5.27B -8,787.83%
US
$1.95B -3,312.74%
NL
$-4.02B 6,514.73%
AU
$-3.09B 4,984.33%
US
- -
CH